Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Yeung

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
Leukemia Research|April 15, 2019
Compound mutations in CML-imaginary bogeyman or real arch-nemesis?David T Yeung
Hematology. American Society of Hematology. Education Program|December 13, 2012
Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?David T Yeung, Susan Branford
Leukemia & Lymphoma|December 22, 2010
Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?David T Yeung, Deborah L White
Proceedings of the American Thoracic Society|July 6, 2010
The CounterACT Research Network: basic mechanisms and practical applicationsDavid A Jett, David T Yeung
Critical Reviews in Oncogenesis|April 5, 2012
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemiaDavid T Yeung, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|February 20, 2015
Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitorsDavid T Yeung, Michael J Mauro
Experimental Eye Research|June 18, 2022
Supporting discovery and development of medical countermeasures for chemical injury to eye and skinHoumam Araj, Hung Tseng, David T Yeung
Proceedings of the National Academy of Sciences of the United States of America|April 1, 2024
Elements of successful NIH grant applicationsHoumam Araj, Leroy Worth, David T Yeung
Blood|April 25, 2022
Asciminib: a new therapeutic option in chronic-phase CML with treatment failureDavid T Yeung, Naranie Shanmuganathan, Timothy P Hughes
Translational Vision Science & Technology|November 17, 2020
Ocular Surface - Merging Challenges and OpportunitiesHoumam Araj, Santa J Tumminia, David T Yeung
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Leukemia Research|April 15, 2019
Compound mutations in CML-imaginary bogeyman or real arch-nemesis?David T Yeung
Hematology. American Society of Hematology. Education Program|December 13, 2012
Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?David T Yeung, Susan Branford
Leukemia & Lymphoma|December 22, 2010
Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?David T Yeung, Deborah L White
Proceedings of the American Thoracic Society|July 6, 2010
The CounterACT Research Network: basic mechanisms and practical applicationsDavid A Jett, David T Yeung
Critical Reviews in Oncogenesis|April 5, 2012
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemiaDavid T Yeung, Timothy P Hughes
Hematology. American Society of Hematology. Education Program|February 20, 2015
Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitorsDavid T Yeung, Michael J Mauro
Experimental Eye Research|June 18, 2022
Supporting discovery and development of medical countermeasures for chemical injury to eye and skinHoumam Araj, Hung Tseng, David T Yeung
Proceedings of the National Academy of Sciences of the United States of America|April 1, 2024
Elements of successful NIH grant applicationsHoumam Araj, Leroy Worth, David T Yeung
Blood|April 25, 2022
Asciminib: a new therapeutic option in chronic-phase CML with treatment failureDavid T Yeung, Naranie Shanmuganathan, Timothy P Hughes
Translational Vision Science & Technology|November 17, 2020
Ocular Surface - Merging Challenges and OpportunitiesHoumam Araj, Santa J Tumminia, David T Yeung
Pageof 11